GlassScriptPhysician profile
Julie L Drew
NPI 1568520658
$2,420.83
in general payments reported to CMS, 2019-2025
22 companies · $810 in 2025
The $810 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.14 · 2022: $87.96 · 2023: $591 · 2024: $919 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $358.27 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $351.46 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $326.09 | 2024-2025 | Airsupra, Farxiga |
| Abbott Laboratories | $236.56 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $202.74 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $164.58 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $139.39 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $138.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $97.80 | 2021-2025 | Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $59.19 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.31 | 2023-2024 | Jardiance |
| Astellas Pharma US INC | $44.41 | 2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.00 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $36.29 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $30.29 | 2024-2025 | Repatha, Otezla, Otezla |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $25.44 | 2025 | |
| Boston Scientific Corporation | $24.76 | 2022 | |
| Bausch Health US, LLC | $24.29 | 2023 | Wellbutrin, Aplenzin |
| Eisai INC. | $21.61 | 2025 | |
| Sonex Health, INC. | $15.64 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.75 | 2022 | |
| Tris Pharma INC | $14.68 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Drew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.